UNSPSC 51182023: Mebolazine

This classification denotes an anabolic steroid with the molecular formula C42H68N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69C642I19V, chemically known as 17beta-hydroxy-2alpha,17-dimethyl-5alpha-androstan-3-one azine but generally known as mebolazine, which bears US NIH Compound Identifier 9571069. European Medicines Agency schedules Mebolazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08666MIG.

UNSPSC 51182023 Mebolazine is a Commodity code identifying a specific pharmaceutical product, but recent state and local procurement activity under this code shows minimal direct solicitation—the single identified opportunity involves a multistate cooperative purchasing agreement for generic pharmaceuticals and over-the-counter products that may include mebolazine among hundreds of other pharmaceuticals, rather than a focused buy of mebolazine alone. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 seeking pharmaceutical manufacturers to supply generic multi-source drugs and OTC products to participating state and local government facilities across Minnesota and Oregon. The scope encompasses manufacturers capable of delivering products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with cGMP certification, DSCSA compliance, and demonstrated relationships with at least two of the three wholesalers. Pricing is weighted as the primary evaluation criterion (75 percent), with secondary emphasis on fixed pricing commitment (10 percent), price competitiveness, EDI capability (5 percent), administrative fee compliance (5 percent), and data format requirements (5 percent).

The geographic footprint is limited to Minnesota and Oregon based on the identified recent opportunity. MMCAP's RFP (S1070000015802) targets an effective contract award date of July 1, 2026, with responses due March 26, 2026 and a questions deadline of February 18, 2026. The procurement structure allows for sole, dual, or multi-awards based on therapeutic considerations and patient safety, with contract terms of two years for new vendors and optional extensions at MMCAP's discretion. No specific dollar values, set-aside designations, or budget ranges are disclosed. The absence of additional recent opportunities under this commodity code suggests that mebolazine purchasing by state and local governments, if it occurs, is bundled into broader pharmaceutical cooperative agreements rather than procured as a standalone product line.